{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:10:31Z","timestamp":1790892631534,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,28]]},"DOI":"10.7759\/cureus.76499","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T10:03:43Z","timestamp":1735380223000},"source":"Crossref","is-referenced-by-count":3,"title":["Roxadustat-Induced Central Hypothyroidism Masked by Uremia at the Initiation of Hemodialysis: A Case Report"],"prefix":"10.7759","author":[{"given":"Mariko","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikuni","family":"Nagayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayana","family":"Ichikura-Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.04.003","article-title":"Phase 3 study of roxadustat to treat anemia in non-dialysis-dependent CKD","volume":"6","author":"Akizawa T","year":"2021","unstructured":"Akizawa T, Iwasaki M, Otsuka T, Yamaguchi Y, Reusch M. Phase 3 study of roxadustat to treat anemia in non-dialysis-dependent CKD. Kidney Int Rep. 2021, 6:1810-28. 10.1016\/j.ekir.2021.04.003","journal-title":"Kidney Int Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.12892","article-title":"Treatment of renal anemia in patients with hemodialysis using hypoxia-inducible factor (HIF) Stabilizer, Roxadustat: a short-term clinical study","volume":"36","author":"Mima A","year":"2022","unstructured":"Mima A, Horii Y. Treatment of renal anemia in patients with hemodialysis using hypoxia-inducible factor (HIF) Stabilizer, Roxadustat: a short-term clinical study. In Vivo. 2022, 36:1785-9. 10.21873\/invivo.12892","journal-title":"In Vivo"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.13148","article-title":"Enarodustat treatment for renal anemia in patients with non-dialysis chronic kidney disease","volume":"37","author":"Mima A","year":"2023","unstructured":"Mima A. Enarodustat treatment for renal anemia in patients with non-dialysis chronic kidney disease. In Vivo. 2023, 37:825-9. 10.21873\/invivo.13148","journal-title":"In Vivo"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174583","article-title":"Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: advantages and disadvantages","volume":"912","author":"Mima A","year":"2021","unstructured":"Mima A. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: advantages and disadvantages. Eur J Pharmacol. 2021, 912:174583. 10.1016\/j.ejphar.2021.174583","journal-title":"Eur J Pharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2019.10.002","article-title":"Revealing a mutant-induced receptor allosteric mechanism for the thyroid hormone resistance","volume":"20","author":"Yao B","year":"2019","unstructured":"Yao B, Wei Y, Zhang S, et al.. Revealing a mutant-induced receptor allosteric mechanism for the thyroid hormone resistance. iScience. 2019, 20:489-96. 10.1016\/j.isci.2019.10.002","journal-title":"iScience"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.13519","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors and hypothyroidism: an analysis of the Japanese pharmacovigilance database","volume":"38","author":"Tanaka H","year":"2024","unstructured":"Tanaka H, Tani A, Onoda T, Ishii T. Hypoxia-inducible factor prolyl hydroxylase inhibitors and hypothyroidism: an analysis of the Japanese pharmacovigilance database. In Vivo. 2024, 38:917-22. 10.21873\/invivo.13519","journal-title":"In Vivo"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-021-02304-2","article-title":"Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis","volume":"22","author":"Ichii M","year":"2021","unstructured":"Ichii M, Mori K, Miyaoka D, et al.. Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis. BMC Nephrol. 2021, 22:104. 10.1186\/s12882-021-02304-2","journal-title":"BMC Nephrol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab007","article-title":"Roxadustat and thyroid-stimulating hormone suppression","volume":"14","author":"Tokuyama A","year":"2021","unstructured":"Tokuyama A, Kadoya H, Obata A, Obata T, Sasaki T, Kashihara N. Roxadustat and thyroid-stimulating hormone suppression. Clin Kidney J. 2021, 14:1472-4. 10.1093\/ckj\/sfab007","journal-title":"Clin Kidney J"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.1186\/s41100-024-00537-z","article-title":"Roxadustat and transfusional iron overload induced hypothyroidism in a hemodialysis patient: a case report with a literature review","volume":"10","author":"Yamashita C","year":"2024","unstructured":"Yamashita C, Hirai Y, Nishigaito T, et al.. Roxadustat and transfusional iron overload induced hypothyroidism in a hemodialysis patient: a case report with a literature review. Ren Replace Ther. 2024, 10:20.","journal-title":"Ren Replace Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2024.2410375","article-title":"Roxadustat has risks of reversible central hypothyroidism in patients undergoing hemodialysis: a single-center retrospective cohort study","volume":"46","author":"Otsuka E","year":"2024","unstructured":"Otsuka E, Kitamura M, Funakoshi S, Mukae H, Nishino T. Roxadustat has risks of reversible central hypothyroidism in patients undergoing hemodialysis: a single-center retrospective cohort study. Ren Fail. 2024, 46:2410375. 10.1080\/0886022X.2024.2410375","journal-title":"Ren Fail"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.9400","article-title":"Low cholesterol levels are good markers for central hypothyroidism in case with dialysis using roxadustat","volume":"12","author":"Kita S","year":"2024","unstructured":"Kita S, Okuyama H, Kondo T, et al.. Low cholesterol levels are good markers for central hypothyroidism in case with dialysis using roxadustat. Clin Case Rep. 2024, 12:e9400. 10.1002\/ccr3.9400","journal-title":"Clin Case Rep"},{"key":"ref12","article-title":"Disorders of the Thyroid Gland","author":"Jameson JL","year":"2012","unstructured":"Jameson JL, Weetman AP. Disorders of the Thyroid Gland. Harrison\u2019s Principles of Internal Medicine, Vol. 2. Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J (ed): McGraw-Hill, USA; 2012. 2919:20."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo S","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, et al.. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009, 53:982-92. 10.1053\/j.ajkd.2008.12.034","journal-title":"Am J Kidney Dis"},{"key":"ref14","article-title":"Low-T3\/Low-T4 syndrome","volume":"85","author":"Nishikawa M","year":"1996","unstructured":"Nishikawa M, Toyota N, Inada M. Low-T3\/Low-T4 syndrome. Nihon Naika Gakkai Zasshi. 1996, 85:772-6.","journal-title":"Nihon Naika Gakkai Zasshi"},{"key":"ref15","doi-asserted-by":"crossref","DOI":"10.2169\/naika.109.550","article-title":"Diagnosis of thyroid diseases and its pitfalls","volume":"109","author":"Yamada M","year":"2020","unstructured":"Yamada M, Nakajima Y. Diagnosis of thyroid diseases and its pitfalls. Nihon Naika Gakkai Zasshi. 2020, 109:550-5.","journal-title":"Nihon Naika Gakkai Zasshi"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv318","article-title":"2015 ESC Guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC) endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS)","volume":"36","author":"Adler Y","year":"2015","unstructured":"Adler Y, Charron P, Imazio M, et al.. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC) endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015, 36:2921-64. 10.1093\/eurheartj\/ehv318","journal-title":"Eur Heart J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2017.11.048","article-title":"Uremic pericarditis in patients with end stage renal disease: prevalence, symptoms and outcome in 2017","volume":"36","author":"Bentata Y","year":"2018","unstructured":"Bentata Y, Hamdi F, Chemlal A, Haddiya I, Ismaili N, El Ouafi N. Uremic pericarditis in patients with end stage renal disease: prevalence, symptoms and outcome in 2017. Am J Emerg Med. 2018, 36:464-6. 10.1016\/j.ajem.2017.11.048","journal-title":"Am J Emerg Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/328051-roxadustat-induced-central-hypothyroidism-masked-by-uremia-at-the-initiation-of-hemodialysis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T10:03:45Z","timestamp":1735380225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/328051-roxadustat-induced-central-hypothyroidism-masked-by-uremia-at-the-initiation-of-hemodialysis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,28]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.76499","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,28]]}}}